# US 10,478,438 B2 · Treatment of organophosphate exposure with ocinaplon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,438 B2
- Document ID: US10478438B2
- Status: Granted
- Kind: B2
- Application number: 13/124,366
- Filed: 2009-10-16
- Published: 2011-10-06
- Granted: 2019-11-19
- Earliest claimed: 2008-10-16
- Applicants: David Reed Helton; Ernest Pfadenhauer
- Inventors: David Reed Helton; Ernest Pfadenhauer
- Web page: https://patentgrep.com/patent/US10478438B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a pyrazolopyrimidine compound such as ocinaplon, zaleplon, indiplon, or divaplon.

## Claims

### Claim 1

A method of treating exposure to sarin, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ocinaplon.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises a pharmaceutically acceptable excipient in combination with the ocinaplon.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is administered by an administrative route selected from the group consisting of intravenous, oral, topical, intraperitoneal, intravesical, transdermal, nasal, rectal, vaginal, intramuscular, intradermal, subcutaneous and intrathecal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition is administered to the subject following exposure of the subject to sarin.

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition is administered to the subject within one hour following exposure of the subject to sarin.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition is administered to the subject within five minutes following exposure of the subject to sarin.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition is administered to the subject within one minute following exposure of the subject to sarin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition is administered to the subject prior to exposure of the subject to sarin.